Board of Directors
- Jim Matheson Chairman
- Arnold J. Levine, Ph.D. Director
- Michael R. Pavia, Ph.D. Director
- Michael Grey Director
Jim Matheson, Chairman
Mr. Jim Matheson joined the Selventa Board of Directors in 2005 and became Chairman in 2008. In his current role, he helps define the company’s strategic vision and brings value to Selventa’s customers and prospects based on his 20 years of technology and leadership experience.
Since becoming a General Partner with Flagship Ventures in 2000, Mr. Matheson focused on creating and funding new ventures in special technologies, sustainability and clean technology fields. He has held several roles designing, engineering and deploying sophisticated technology platforms. Previously, Mr. Matheson, a retired Commander in the U.S. Naval Reserves, served as a Navy F-14 and FA-18 pilot. He also had extensive experience in emerging aircraft and weapons system design, testing and procurement, and was involved deeply in many of the military’s IT modernization initiatives.
Mr. Matheson received an M.B.A. from The Harvard Business School and a Bachelor of Science degree in systems engineering with honors from The United States Naval Academy.
Arnold J. Levine, Ph.D., Director
Dr. Arnold J. Levine joined the Selventa Board of Directors in 2010 and currently provides deep scientific expertise and broad commercial acumen based on over 50 years of experience. He is a recognized leader in oncology and systems biology. He has authored more than 400 scientific papers and has received many awards for his scientific contributions, including his work in establishing p53 as a tumor suppressor. In recognition of his contributions, Dr. Levine was elected to the National Academy of Sciences in 1991 and to its Institute of Medicine in 1995.
Currently, he is a professor in the School of Natural Sciences at the Institute for Advanced Study (IAS) and leads The Simons Center for Systems Biology at the Institute, which he established. Dr. Levine previously served as President and Chief Executive Officer of the Rockefeller University in New York City from 1998 to 2002, as well as Heilbrunn Professor of Cancer Biology and laboratory head until joining the Institute in 2002. In 1984, he was named Harry C. Weiss Professor in the Life Sciences in the Department of Molecular Biology, a position he held until 1998. He chaired the Department between 1984 and 1996. Dr. Levine began his scientific career as a member of the faculty of the Biochemistry Department of Princeton University from 1968 to 1979 and also served as chair and professor in the Department of Microbiology at the State University of New York, Stony Brook, School of Medicine.
Dr. Levine completed his postdoctoral fellowship in public health service at the California Institute of Technology. He received his Ph.D. in microbiology from the University of Pennsylvania, School of Medicine and Bachelor of Arts from Harpur College, State University of New York. He also holds honorary degrees from, among other institutions, Rider University, the University of Medicine and Dentistry of New Jersey, the Weizmann Institute of Science, and the University Pierre and Marie Curie in Paris.
Michael R. Pavia, Ph.D., Director
Dr. Michael R. Pavia joined the Selventa Board of Directors in 2005. He has over 25 years of experience in pharmaceutical research and discovery.
Dr. Pavia is currently an independent consultant to energy and biotechnology companies. Previously, he was an Entrepreneur-in-Residence at Oxford Bioscience Partners after joining the firm in 2002. Dr. Pavia also served as the Chief Technology Officer at Millennium Pharmaceuticals, where his major focus was to improve the productivity of the drug discovery and development process through the appropriate use of new technologies. He was formerly a Vice President of Cambridge Research at Sphinx Pharmaceuticals, which was sold to Eli Lilly; He was responsible for developing high-throughput combinatorial chemistry capabilities. Prior to that, he held senior scientific positions in the Department of Chemistry at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert.
Dr. Pavia received Ph.D. in organic chemistry from the University of Pennsylvania and a Bachelor of Science in chemistry from Lehigh University.
Michael Grey, Director
Mike Grey joined the Selventa Board of Directors in 2011. He has over 30 years of experience in the biopharmaceutical industry.
Mr. Grey is currently a Venture Partner at Pappas Ventures and CEO of Lumena Pharmaceuticals, a private biotech company. Prior to joining Pappas Ventures, he held multiple Chief Executive Officer positions in the pharmaceutical industry. He served as the President and CEO of Auspex Pharmaceuticals, CEO of SGX Pharmaceuticals (formerly Structural GenomiX) which was eventually sold to Eli Lilly, and President and CEO of Trega Biosciences until its acquisition by Lion Bioscience. He was also President of BioChem Therapeutics, the pharmaceutical arm of BioChem Pharma. Prior to these, Mr. Grey held various roles with Glaxo Holdings plc and Glaxo Inc., including positions as Vice President of Corporate Development and Director of International Licensing. Mr. Grey is a board member at BioMarin Pharmaceutical.
He received a Bachelor of Science in chemistry from the University of Nottingham in the United Kingdom.